nach oben

Erschienen in:

20.04.2018 | Clinical Study

¹⁸F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

verfasst von: Chirag B. Patel, Elisa Fazzari, Ararat Chakhoyan, Jingwen Yao, Catalina Raymond, Huytram Nguyen, Jasmine Manoukian, Nhung Nguyen, Whitney Pope, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Johannes Czernin, Albert Lai, Benjamin M. Ellingson

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To report the potential value of pre-operative ¹⁸F-FDOPA PET and anatomic MRI in diagnosis and prognosis of glioma patients.

Methods

Forty-five patients with a pathological diagnosis of glioma with pre-operative ¹⁸F-FDOPA PET and anatomic MRI were retrospectively examined. The volume of contrast enhancement and T2 hyperintensity on MRI images along with the ratio of maximum ¹⁸F-FDOPA SUV in tumor to normal tissue (T/N SUV_max) were measured and used to predict tumor grade, molecular status, and overall survival (OS).

Results

A significant correlation was observed between WHO grade and: the volume of contrast enhancement (r = 0.67), volume of T2 hyperintensity (r = 0.42), and ¹⁸F-FDOPA uptake (r = 0.60) (P < 0.01 for each correlation). The volume of contrast enhancement and ¹⁸F-FDOPA T/N SUV_max were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I–III), as well as for high-grade gliomas (WHO III–IV) compared with low-grade gliomas (WHO I–II). Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and ¹⁸F-FDOPA T/N SUV_max could each differentiate patient groups. No significant differences in ¹⁸F-FDOPA uptake were observed by IDH or MGMT status. Multivariable Cox regression suggested age (HR 1.16, P = 0.0001) and continuous measures of ¹⁸F-FDOPA PET T/N SUV_max (HR 4.43, P = 0.016) were significant prognostic factors for OS in WHO I–IV gliomas.

Conclusions

Current findings suggest a potential role for the use of pre-operative ¹⁸F-FDOPA PET in suspected glioma. Increased ¹⁸F-FDOPA uptake may not only predict higher glioma grade, but also worse OS.

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62CrossRefPubMedPubMedCentral

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed

Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol 18:1313–1318CrossRefPubMedPubMedCentral

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316CrossRefPubMedPubMedCentral

Ellingson BM, Wen PY, Cloughesy TF (2018) Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol 20(4):457–471CrossRefPubMed

Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S (2016) Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 60:66–73CrossRefPubMed

Bund C, Heimburger C, Imperiale A, Lhermitte B, Chenard MP, Lefebvre F, Kremer S, Proust F, Namer IJ (2017) FDOPA PET-CT of nonenhancing brain tumors. Clin Nucl Med 42:250–257CrossRefPubMed

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199–1208CrossRefPubMedPubMedCentral

Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH (2009) Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 50:1962–1968CrossRefPubMed

10.

Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC (2012) 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53:1709–1715CrossRefPubMed

11.

Nihashi T, Dahabreh IJ, Terasawa T (2013) Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 34:944–950 (S941–911)CrossRefPubMed

12.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

13.

Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942CrossRefPubMed

14.

Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, Baum RP (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36:841–847CrossRefPubMed

15.

Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ (2013) Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 54:229–235CrossRefPubMed

16.

Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53:207–214CrossRefPubMed

17.

Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J (2012) Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med 53:393–398CrossRefPubMed

18.

Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, Smith J, Rose S (2015) Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma. Nucl Med Biol 42:788–795CrossRefPubMed

19.

Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W (2010) Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 51:1532–1538CrossRefPubMed

20.

Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, Schillaci O, Floris R, Marzi S, Fabi A, Pace A (2015) The role of PET [18F]FDOPA in evaluating low-grade glioma. Anticancer Res 35:5117–5122PubMed

21.

Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 15:1058–1067CrossRefPubMedPubMedCentral

22.

Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, Pietrzyk U (1996) F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 37:1180–1182PubMed

23.

Dowson N, Thomas P, Fay M, Jeffree RL, Gal Y, Bourgeat P, Smith J, Winter C, Coulthard A, Salvado O, Crozier S, Rose S (2014) Early prediction of treatment response in advanced gliomas with (18)F-dopa positron-emission tomography. Curr Oncol 21:e172-178

24.

Janvier L, Olivier P, Blonski M, Morel O, Vignaud JM, Karcher G, Taillandier L, Verger A (2015) Correlation of SUV-derived indices with tumoral aggressiveness of gliomas in static 18F-FDOPA PET: use in clinical practice. Clin Nucl Med 40:e429–435CrossRef

25.

Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Lohr M, Herrmann K (2014) Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 55:1611–1616CrossRefPubMed

26.

Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W (2009) 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 71:242–248CrossRefPubMed

27.

Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R, Capelle L, Guillevin R, Foehrenbach H, Buvat I (2013) Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT. Clin Nucl Med 38:81–87CrossRefPubMed

28.

Rose S, Fay M, Thomas P, Bourgeat P, Dowson N, Salvado O, Gal Y, Coulthard A, Crozier S (2013) Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC? Am J Neuroradiol 34:758–764CrossRefPubMed

29.

Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC (2007) 18F-FDOPA kinetics in brain tumors. J Nucl Med 48:1651–1661CrossRefPubMed

30.

Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34:878–883CrossRefPubMed

31.

Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF (2017) Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol 19:89–98CrossRefPubMed

32.

Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200–210CrossRefPubMed

33.

Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM (2014) Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 16:414–420CrossRefPubMed

34.

Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046–2053CrossRefPubMed

35.

Nuyts J, Michel C, Dupont P (2001) Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging 20:365–375CrossRefPubMed

36.

Ideguchi M, Nishizaki T, Ikeda N, Okamura T, Tanaka Y, Fujii N, Ohno M, Shimabukuro T, Kimura T, Ikeda E, Suga K (2018) A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement. J Neurooncol. https://doi.org/10.1007/s11060-018-2821-9 PubMedCrossRef

37.

Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, Chinot O, Figarella-Branger D, Guedj E (2017) IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur J Nucl Med Mol Imaging 44:1306–1311CrossRefPubMed

38.

Ochiai H, Morishita T, Onda K, Sugiyama H, Maruo T (2012) Canine Lat1: molecular structure, distribution and its expression in cancer samples. J Vet Med Sci 74:917–922CrossRefPubMed

39.

Duelli R, Enerson BE, Gerhart DZ, Drewes LR (2000) Expression of large amino acid transporter LAT1 in rat brain endothelium. J Cereb Blood Flow Metab 20:1557–1562CrossRefPubMed

40.

Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, Giannini C, Laack NN, Parney IF, Lowe VJ, Brinkmann DH, Sarkaria JN (2013) The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol 111:11–18CrossRefPubMed

Titel: 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study
verfasst von: Chirag B. Patel
Elisa Fazzari
Ararat Chakhoyan
Jingwen Yao
Catalina Raymond
Huytram Nguyen
Jasmine Manoukian
Nhung Nguyen
Whitney Pope
Timothy F. Cloughesy
Phioanh L. Nghiemphu
Johannes Czernin
Albert Lai
Benjamin M. Ellingson
Publikationsdatum: 20.04.2018
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2877-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

GOLPH3 promotes glioma progression via facilitating JAK2–STAT3 pathway activation

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009–2014

Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10

Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide

Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study